Haematologica, 2014 Intravenous immunoglobulin replacement therapy represents the standard treatment for hypogammaglobulinemia secondary to B-cell lymphoproliferative disorders. Subcutaneous immunoglobulin infusion is an effective, safe and well-tolerated treatment approach
Nicolò Compagno +3 more
doaj +1 more source
Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin [PDF]
, 2016 The therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythematosus (SLE) patients is well established. However, side effects might limit its use and lead to the consideration of therapeutic alternatives, such as the ...
Brasileiro, A +3 more
core +1 more source
Pre-B-cell acute lymphoblastic leukemia with bulk extramedullary disease and chromosome 22 (EWSR1) rearrangement masquerading as Ewing sarcoma [PDF]
, 2010 We report a 2-year-old female with a subcutaneous tumor who was initially misdiagnosed as suffering from Ewing sarcoma with a positive EWSR1 rearrangement and EWS/FLI1 transcript.
Jakovljević, Gordana +6 more
core +1 more source
Subcutaneous immunoglobulin: opportunities and outlook
Clinical and Experimental Immunology, 2009 Summary Immunoglobulin (Ig) administration via the subcutaneous (s.c.) route has become increasingly popular in recent years. The method does not require venous access, is associated with few systemic side effects and has been reported to improve patients' quality of life. One current limitation to its use is the large volumes which need
S, Misbah +6 more
openaire +3 more sources
Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review [PDF]
, 2014 BACKGROUND: Intravenous (IV) drug delivery is commonly used for its rapid administration and immediate drug effect. Most studies compare IV to subcutaneous (SC) delivery in terms of safety and efficacy, but little is known about what patients prefer.
Fallowfield, Lesley J +3 more
core +1 more source
New Frontiers in Subcutaneous Immunoglobulin Treatment [PDF]
Biologics in Therapy, 2011 Subcutaneous immunoglobulin (SCIG) treatment provides stable serum immunoglobulin G (IgG) levels, is associated with fewer systemic adverse events than intravenous immunoglobulin (IVIG) treatment, and offers the convenience of home therapy. In clinical practice, IVIG is still used preferentially for initiation of treatment in newly diagnosed patients ...
Jolles, Stephen +6 more
openaire +2 more sources
Frontiers in Neurology, 2020 Background: We previously reported an open-label prospective trial of subcutaneous immunoglobulin (SCIg) in mild to moderate exacerbations of myasthenia gravis (MG).
Brendan N. Putko +2 more
doaj +1 more source
Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection [PDF]
, 2014 Background/Purpose: A proper adjuvant has a relevant role in vaccine formulations to generate an effective immune response. In this study, total Leishmania antigen (TLA) formulated with Montanide ISA 763 or R848 as adjuvants were evaluated as a first ...
Cargnelutti, Diego Esteban +6 more
core +1 more source
Serum levels of RBP4 and adipose tissue levels of PTP1B are increased in obese men resident in northeast Scotland without associated changes in ER stress response genes [PDF]
, 2012 Peer reviewedPublisher ...
Agouni, Abdelali +3 more
core +3 more sources
Haematologica, 2014 Examination of abdominal subcutaneous fat aspirates is a practical, sensitive and specific method for the diagnosis of systemic amyloidosis. Here we describe the development and implementation of a clinical assay using mass spectrometry-based proteomics ...
Julie A. Vrana +9 more
doaj +1 more source